Motexafin Gadolinium
drugOn this page
Also known as API-GP3FP-GP1GADOLINIUM TEXAPHYRINGD TEXAPHYRINGD-TEXGD-TEXAPHYRINMotexafin gadolinium anhydrousMotexafin gadolinium hydrateNSC-695238PCI-0120Xcytrin
Summary
Motexafin Gadolinium (CHEMBL3544910) is a phase-3 clinical-stage small molecule; indicated across 23 conditions including brain neoplasm and plasma cell myeloma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 23 conditions
- Clinical trials: 31
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3544910 |
| Name | Motexafin Gadolinium |
| Type | Small molecule |
| Max phase | 3 |
Also known as: API-GP3, FP-GP1, GADOLINIUM TEXAPHYRIN, GD TEXAPHYRIN, GD-TEX, GD-TEXAPHYRIN, Motexafin gadolinium, Motexafin gadolinium anhydrous, Motexafin gadolinium hydrate, NSC-695238, PCI-0120, Xcytrin
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
23 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| brain neoplasm | 3 | MONDO:0021211 | EFO:0003833 |
| plasma cell myeloma | 2 | MONDO:0009693 | EFO:0001378 |
| non-small cell lung carcinoma | 2 | MONDO:0005233 | EFO:0003060 |
| B-cell chronic lymphocytic leukemia | 2 | MONDO:0004948 | EFO:0000095 |
| adenocarcinoma | 2 | MONDO:0004970 | EFO:0000228 |
| renal cell carcinoma | 2 | MONDO:0005086 | EFO:0000681 |
| non-Hodgkin lymphoma | 2 | MONDO:0018908 | EFO:0005952 |
| central nervous system neoplasm | 2 | MONDO:0006130 | EFO:1000158 |
| kidney cancer | 2 | MONDO:0002367 | MONDO:0002367 |
| lung neoplasm | 2 | MONDO:0021117 | MONDO:0008903 |
| kidney neoplasm | 2 | MONDO:0021163 | EFO:0003865 |
| glioblastoma | 1 | MONDO:0018177 | EFO:0000519 |
| oligodendroglioma | 1 | MONDO:0016695 | EFO:0000632 |
| exocrine pancreatic carcinoma | 1 | MONDO:0005192 | EFO:0002618 |
| gliosarcoma | 1 | MONDO:0016681 | EFO:1001465 |
| gallbladder neoplasm | 1 | MONDO:0021253 | MONDO:0005411 |
| leukemia | 1 | MONDO:0005059 | EFO:0000565 |
| lymphoma | 1 | MONDO:0005062 | EFO:0000574 |
| paraganglioma | 1 | MONDO:0000448 | EFO:1000453 |
4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 31.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 12 |
| PHASE1 | 11 |
| PHASE1/PHASE2 | 3 |
| Not specified | 3 |
| PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00054795 | PHASE3 | COMPLETED | Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART) |
| NCT00022256 | PHASE2 | COMPLETED | Motexafin Gadolinium Plus Radiation Therapy to the Brain in Treating Patients With Newly Diagnosed Glioblastoma Multiforme |
| NCT00076401 | PHASE2 | TERMINATED | A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL) |
| NCT00086034 | PHASE2 | COMPLETED | Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin’s Lymphoma |
| NCT00089284 | PHASE1/PHASE2 | TERMINATED | Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL |
| NCT00100711 | PHASE2 | TERMINATED | Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| NCT00121420 | PHASE2 | TERMINATED | Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases |
| NCT00129844 | PHASE2 | COMPLETED | Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer |
| NCT00134186 | PHASE2 | COMPLETED | Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer |
| NCT00290004 | PHASE1/PHASE2 | COMPLETED | Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| NCT00305864 | PHASE1/PHASE2 | COMPLETED | Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma |
| NCT00365183 | PHASE2 | TERMINATED | Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer |
| NCT00373204 | PHASE2 | TERMINATED | Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere) |
| NCT00387790 | PHASE2 | COMPLETED | Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma |
| NCT00514397 | PHASE2 | UNKNOWN | Temozolomide and Radiation Therapy in Treating Young Patients With Pontine Glioma |
| NCT00717587 | PHASE2 | UNKNOWN | Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer |
| NCT00003409 | PHASE1 | COMPLETED | Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme |
| NCT00003410 | PHASE1 | COMPLETED | Motexafin Gadolinium With MRI-Guided Surgery in Treating Patients With High-Grade Gliomas |
| NCT00003411 | PHASE1 | COMPLETED | Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer |
| NCT00003798 | PHASE1 | COMPLETED | Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Cancer of the Pancreas That Cannot Be Removed by Surgery |
| NCT00003909 | PHASE1 | COMPLETED | Motexafin Gadolinium Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma |
| NCT00004262 | PHASE1 | COMPLETED | Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme |
| NCT00005065 | PHASE1 | COMPLETED | Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer |
| NCT00006452 | PHASE1 | COMPLETED | Gadolinium Texaphyrin Plus Radiation Therapy in Treating Patients With Supratentorial Glioblastoma Multiforme |
| NCT00032097 | PHASE1 | COMPLETED | Motexafin Gadolinium in Treating Patients With Glioblastoma Multiforme Who Are Undergoing Radiation Therapy to the Brain |
| NCT00036790 | PHASE1 | COMPLETED | Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer |
| NCT00120939 | PHASE1 | COMPLETED | Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer |
| NCT00734773 | EARLY_PHASE1 | WITHDRAWN | Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL |
| NCT00003736 | Not specified | COMPLETED | MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer |
| NCT01082224 | Not specified | UNKNOWN | Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy |
| NCT01562223 | Not specified | UNKNOWN | Studying Repeated DCE-MRI and DWI in Patients Diagnosed With Prostate Cancer |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: brain neoplasm